CN110448693A - 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 - Google Patents
氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 Download PDFInfo
- Publication number
- CN110448693A CN110448693A CN201910692481.XA CN201910692481A CN110448693A CN 110448693 A CN110448693 A CN 110448693A CN 201910692481 A CN201910692481 A CN 201910692481A CN 110448693 A CN110448693 A CN 110448693A
- Authority
- CN
- China
- Prior art keywords
- aeruginosa
- polymyxin
- colistin
- fluoroquinolones
- pseudomonas aeruginosa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229940124307 fluoroquinolone Drugs 0.000 title claims abstract description 25
- 108010040201 Polymyxins Proteins 0.000 title claims description 13
- 230000003115 biocidal effect Effects 0.000 title description 13
- 229940041153 polymyxins Drugs 0.000 title description 3
- 108010093965 Polymyxin B Proteins 0.000 claims abstract description 41
- 229920000024 polymyxin B Polymers 0.000 claims abstract description 41
- 229960005266 polymyxin b Drugs 0.000 claims abstract description 41
- KNIWPHSUTGNZST-UHFFFAOYSA-N polymyxin E2 Natural products CC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O KNIWPHSUTGNZST-UHFFFAOYSA-N 0.000 claims abstract description 30
- 108010078777 Colistin Proteins 0.000 claims abstract description 27
- 241000589517 Pseudomonas aeruginosa Species 0.000 claims abstract description 27
- 229960003346 colistin Drugs 0.000 claims abstract description 27
- JORAUNFTUVJTNG-BSTBCYLQSA-N n-[(2s)-4-amino-1-[[(2s,3r)-1-[[(2s)-4-amino-1-oxo-1-[[(3s,6s,9s,12s,15r,18s,21s)-6,9,18-tris(2-aminoethyl)-3-[(1r)-1-hydroxyethyl]-12,15-bis(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]butan-2-yl]amino]-3-h Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O.CCC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@H]([C@@H](C)O)CN[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O JORAUNFTUVJTNG-BSTBCYLQSA-N 0.000 claims abstract description 27
- XDJYMJULXQKGMM-UHFFFAOYSA-N polymyxin E1 Natural products CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCN)NC(=O)C(CCN)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCN)NC1=O XDJYMJULXQKGMM-UHFFFAOYSA-N 0.000 claims abstract description 27
- 229960003170 gemifloxacin Drugs 0.000 claims abstract description 26
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims abstract description 24
- 101150026476 PAO1 gene Proteins 0.000 claims abstract description 14
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000003112 inhibitor Substances 0.000 claims abstract description 11
- 241000894006 Bacteria Species 0.000 claims abstract description 8
- SPFYMRJSYKOXGV-UHFFFAOYSA-N Baytril Chemical compound C1CN(CC)CCN1C(C(=C1)F)=CC2=C1C(=O)C(C(O)=O)=CN2C1CC1 SPFYMRJSYKOXGV-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960000740 enrofloxacin Drugs 0.000 claims abstract description 8
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 229960003405 ciprofloxacin Drugs 0.000 claims abstract description 6
- 229960004954 sparfloxacin Drugs 0.000 claims abstract description 6
- DZZWHBIBMUVIIW-DTORHVGOSA-N sparfloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(N)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F DZZWHBIBMUVIIW-DTORHVGOSA-N 0.000 claims abstract description 6
- XAGMUUZPGZWTRP-ZETCQYMHSA-N LSM-5745 Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1C1(N)CC1 XAGMUUZPGZWTRP-ZETCQYMHSA-N 0.000 claims abstract description 5
- 229960002625 pazufloxacin Drugs 0.000 claims abstract description 5
- XBHBWNFJWIASRO-UHFFFAOYSA-N 6-fluoro-1-(4-fluorophenyl)-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1=CC=C(F)C=C1 XBHBWNFJWIASRO-UHFFFAOYSA-N 0.000 claims abstract description 4
- 229960003702 moxifloxacin Drugs 0.000 claims abstract description 4
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims abstract description 4
- 229950007734 sarafloxacin Drugs 0.000 claims abstract description 4
- WUWFMDMBOJLQIV-UHFFFAOYSA-N 7-(3-aminopyrrolidin-1-yl)-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1C(N)CCN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1=CC=C(F)C=C1F WUWFMDMBOJLQIV-UHFFFAOYSA-N 0.000 claims abstract description 3
- DPSPPJIUMHPXMA-UHFFFAOYSA-N 9-fluoro-5-methyl-1-oxo-6,7-dihydro-1H,5H-pyrido[3,2,1-ij]quinoline-2-carboxylic acid Chemical compound C1CC(C)N2C=C(C(O)=O)C(=O)C3=C2C1=CC(F)=C3 DPSPPJIUMHPXMA-UHFFFAOYSA-N 0.000 claims abstract description 3
- BPFYOAJNDMUVBL-UHFFFAOYSA-N LSM-5799 Chemical compound C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3N(C)COC1=C32 BPFYOAJNDMUVBL-UHFFFAOYSA-N 0.000 claims abstract description 3
- QIPQASLPWJVQMH-DTORHVGOSA-N Orbifloxacin Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=C(F)C(F)=C2C(=O)C(C(O)=O)=CN(C3CC3)C2=C1F QIPQASLPWJVQMH-DTORHVGOSA-N 0.000 claims abstract description 3
- PWNMXPDKBYZCOO-UHFFFAOYSA-N Prulifloxacin Chemical compound C1=C2N3C(C)SC3=C(C(O)=O)C(=O)C2=CC(F)=C1N(CC1)CCN1CC=1OC(=O)OC=1C PWNMXPDKBYZCOO-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960000702 flumequine Drugs 0.000 claims abstract description 3
- 229960002531 marbofloxacin Drugs 0.000 claims abstract description 3
- 229960001699 ofloxacin Drugs 0.000 claims abstract description 3
- 229960004780 orbifloxacin Drugs 0.000 claims abstract description 3
- 229960004236 pefloxacin Drugs 0.000 claims abstract description 3
- FHFYDNQZQSQIAI-UHFFFAOYSA-N pefloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCN(C)CC1 FHFYDNQZQSQIAI-UHFFFAOYSA-N 0.000 claims abstract description 3
- 229960001224 prulifloxacin Drugs 0.000 claims abstract description 3
- 229950008187 tosufloxacin Drugs 0.000 claims abstract description 3
- -1 lavo-ofloxacin Chemical compound 0.000 claims abstract 2
- 239000003814 drug Substances 0.000 claims description 15
- 230000035945 sensitivity Effects 0.000 claims description 14
- 229940079593 drug Drugs 0.000 claims description 12
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 206010035664 Pneumonia Diseases 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 4
- 206010040047 Sepsis Diseases 0.000 claims description 4
- 208000037815 bloodstream infection Diseases 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 208000008745 Healthcare-Associated Pneumonia Diseases 0.000 claims description 3
- 230000001524 infective effect Effects 0.000 claims description 3
- 208000009470 Ventilator-Associated Pneumonia Diseases 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 239000004576 sand Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 241001499304 Pseudomonas aeruginosa DK2 Species 0.000 abstract description 2
- 241001240958 Pseudomonas aeruginosa PAO1 Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 9
- 230000009036 growth inhibition Effects 0.000 description 9
- 230000035699 permeability Effects 0.000 description 7
- NWFNSTOSIVLCJA-UHFFFAOYSA-L copper;diacetate;hydrate Chemical compound O.[Cu+2].CC([O-])=O.CC([O-])=O NWFNSTOSIVLCJA-UHFFFAOYSA-L 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 206010059866 Drug resistance Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 235000011888 snacks Nutrition 0.000 description 5
- 229940126680 traditional chinese medicines Drugs 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- KNIWPHSUTGNZST-SSWRVQTPSA-N colistin B Chemical compound CC(C)CCCCC(=O)N[C@@H](CCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCN)C(=O)N[C@H]1CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@H](CCN)NC1=O KNIWPHSUTGNZST-SSWRVQTPSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000037581 Persistent Infection Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000037041 Community-Acquired Infections Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- TZJKHERXIDPDTK-UHFFFAOYSA-N N1=CC=CC2=CC=CC=C12.[F] Chemical compound N1=CC=CC2=CC=CC=C12.[F] TZJKHERXIDPDTK-UHFFFAOYSA-N 0.000 description 1
- 206010029803 Nosocomial infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000004500 asepsis Methods 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 244000052637 human pathogen Species 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明揭示了氟喹诺酮类药物的新用途。即氟喹诺酮类药物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用。其中，所述的氟喹诺酮类药物是吉米沙星，司帕沙星，恩诺沙星，环丙沙星，沙氟沙星，莫西沙星，培氟沙星，妥舒沙星，奥比沙星，普卢利沙星，马波沙星，左氧氟沙星，氟甲喹或/和帕珠沙星；所述铜绿假单胞菌是铜绿假单胞菌DK2或PAO1；所述铜绿假单胞菌抑制剂是多粘菌素B或粘菌素。
Description
技术领域
本发明涉及氟喹诺酮类药物的新用途；具体地说，涉及氟喹诺酮类药物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用。
背景技术
铜绿假单胞菌(P.aeruginosa)是一种严重的可引起危及生命感染的人类病原体。由于过度的内在和获得性抗性机制，多重耐药(MDR)P.aeruginosa对公共健康构成严重威胁。在发达国家，P.aeruginosa负责社区和医院获得性感染，包括医院获得性肺炎(HAP)，呼吸机相关性肺炎(VAP)和血流感染(BSI)(Imperi,Antimicrob.Agents.Chemother.2013,57,996-1005.Puzniak,Antimicrob Agents Chemother.2019,63,e02564.Nagarajan,Chin.Chem.Lett,2014,25,419-422)。此外，P.aeruginosa是囊性纤维化(CysticFibrosis,CF)患者中的常见病原体，易于在该类患者体内建立慢性感染且伴随患者直至生命结束，感染在CF患者中引起极大比例的发病率和死亡率(Anders,Nat.Rev.Microbiol.2012,10,841-851)。P.aeruginosa DK2是自1973年以来从丹麦CF患者体内采集的一种铜绿菌株分离物，其谱系在肺环境中持续存在数十年，在感染患者的同时已发展成独立的亚系统(Marvig,Antimicrob Agents Chemother,2012,56,4519-4521.Yang,Proc Natl Acad Sci U S A,2011,108,7481-7486)。由于极少的抗生素批准和缺乏具有新型作用模式的新抗生素，这类病原体的治疗选择很少。因此，研制能够治疗和/或预防铜绿假单胞菌引起的感染的药物具有临床价值和意义。
多粘菌素(Polymyxin)是一类古老的多肽类抗生素，例如：多粘菌素B(PolymyxinB)和粘菌素(Colistin))，其通过与脂多糖(LPS)核心的脂肪酸和磷酸盐以及革兰氏阴性细菌的脂质A相互作用而引起细胞裂解和死亡(Zhu,Chin.Chem.Lett.2017，28，703-708)。在20世纪80年代早期，Polymyxin类抗生素由于肾毒性发生率很高在大多数地区被废弃使用，随后在过去的30年间，Polymyxin类抗生素再次被用于治疗感染多药耐药革兰氏阴性菌的CF患者。作为慢性感染的CF患者中少数可用且有效的抗生素之一，Polymyxin类抗生素被认为是对抗由革兰氏阴性细菌引起危及生命感染的最后一道防线。但随着最近临床实践中使用的增加，Polymyxin抗性已经产生并迅速传播(Nagarajan,Chin.Chem.Lett,2014,25,419-422.Zhu,Chin.Chem.Lett.2017,28,703-708)。
应对抗药性的紧急情况有两种应对策略，一种是研究一种新型抗生素，具有针对抗性菌株的新型作用模式，但该策略研发周期长，成本高，无法在短时间内缓解临床的困难局面。另一种策略是寻找Polymyxin的增敏剂以恢复抗性菌株对抗生素的敏感性，这种增敏治疗可以保留最后一类抗生素并减少细菌耐药性的产生。重新定位已批准的药物是发现新增敏剂的良好策略，该策略快速有效且成本效益高。
因此，本领域迫切需要一种用于治疗和/或预防由铜绿假单胞菌(P.aeruginosa)引起的细菌感染疾病的Polymyxin类抗生素的增敏剂。同时这也是本发明需要解决的技术问题。
发明内容
氟喹诺酮类药物是目前临床上常用的抗菌药，具有广泛的抗菌谱，主要用于治疗尿路感染、呼吸道等各种组织感染。
本发明的发明人经筛选发现：氟喹诺酮类药物对Polymyxin类抗生素表现出增敏作用。即与某些氟喹诺酮类药物与某些Polymyxin类抗生素联用，对铜绿假单胞菌某些菌株产生优于单独用药的生长抑制作用。
因此，本发明目的一个目的在于，揭示氟喹诺酮类药物的一种新用途：即氟喹诺酮类药物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用；
其中，所述的氟喹诺酮类药物的名称及结构见表1；所述铜绿假单胞菌(P.aeruginosa)是铜绿假单胞菌(P.aeruginosa)DK2(下文简记为“DK2”)或铜绿假单胞菌(P.aeruginosa)PAO1(下文简记为“PAO1”)；所述铜绿假单胞菌(P.aeruginosa)抑制剂是多粘菌素B(Polymyxin B)或粘菌素(Colistin)。
本发明另一个目的在于，提供一种药物组合物。所述药物组合物包含表1所示氟喹诺酮类药物、多粘菌素B(Polymyxin B)或粘菌素(Colistin)和药学上可接受稀释剂和赋形剂等辅料；
其中，氟喹诺酮类药物与多粘菌素B(Polymyxin B)或粘菌素(Colistin)的质量比(0.001～10):1。
此外，本发明还有一个目的在于，公开上述药物组合物的一种用途。即所述药物组合物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用；或，
所述药物组合物在制备治疗和/或预防由铜绿假单胞菌(P.aeruginosa)引起的细菌感染疾病的药物中的应用；
其中，铜绿假单胞菌(P.aeruginosa)是DK2或PAO1；所述铜绿假单胞菌(P.aeruginosa)抑制剂是多粘菌素B(Polymyxin B)或粘菌素(Colistin)；
所述由铜绿假单胞菌(P.aeruginosa)引起的细菌感染疾病包括：由铜绿假单胞菌(P.aeruginosa)感染引起的囊性纤维化，医院获得性肺炎，呼吸机相关性肺炎和血流感染等。
表1
附图说明
图1.为吉米沙星增敏多粘菌素B对PAO1产生生长抑制作用图；
图2.为吉米沙星增加铜绿假单胞菌(P.aeruginosa)细胞外膜的通透性图；
其中，A—吉米沙星增加DK2细胞外膜的通透性图；B—吉米沙星增加PAO1细胞外膜的通透性图。
具体实施方式
下面通过实施例对本发明作进一步阐述，其目的仅在于更好理解本发明的内容，而非限制本发明的保护范围。下列实施例中，DK2的来源为Rau MH,Environ.Microbiol,2012,14,2200-2211，其余菌株、药物和试剂均为市售品。
实施例1
氟喹诺酮类药物增敏多粘菌素B(Polymyxin B)对DK2产生生长抑制作用的棋盘实验。
(1)实验材料和方法
将DK2培养过夜，用新鲜LB培养基稀释至吸光度(OD600)约为0.01。将100μL细菌悬浮液加到96孔板，再加入相应浓度的氟喹诺酮类药物和多粘菌素B，将板在37℃下孵育18小时。分级抑菌浓度(FIC)通过棋盘确定。每种药物的最低抑菌浓度(Minimum InhibitoryConcentration，简记为“MIC”)是肉眼可见无菌生长时的药物浓度。每种药物的FIC计算为(组合使用时药剂的MIC)/(单独使用时药剂的MIC)。FIC指数(FICI)是氟喹诺酮类药物和多粘菌素B的FIC之和。
(2)实验结果
结果见表2。表1所述的氟喹诺酮类药物均可以增敏多粘菌素B，使多粘菌素B的MIC相比单独使用时显著降低，其中吉米沙星，司帕沙星，恩诺沙星，环丙沙星，沙氟沙星，莫西沙星和帕珠沙星能够将多粘菌素B的MIC降低至敏感点(2μg/mL)以下，使耐药DK2恢复对多粘菌素B的敏感性。
其中，FICI为1表明没有相互作用，FICI小于或等于0.5有增敏作用，FICI大于或等于4有拮抗作用。对于DK2，单独使用多粘菌素B时的MIC是512μg/mL，说明DK2对多粘菌素B已经严重耐药。
表2
续表2
a指对于DK2，单独使用氟喹诺酮类药物的MIC。
b指对于DK2，与1μg/mL的氟喹诺酮类药物联用时多粘菌素B的MIC。
c多粘菌素B对铜绿的MIC敏感点≤2μg/mL，耐药点≥8μg/mL；
环丙沙星对铜绿的MIC敏感点≤1μg/mL，耐药点≥4μg/mL；左氧氟沙星对铜绿的MIC敏感点≤2μg/mL，耐药点≥8μg/mL(Wayne,CLSI 2017Document M100-S27)。
d我们将环丙沙星对铜绿的MIC断点应用于吉米沙星，司帕沙星，恩诺沙星，沙氟沙星，莫西沙星，培氟沙星，妥舒沙星，奥比沙星，普卢利沙星，马波沙星，氟甲喹和帕珠沙星。敏感点≤1μg/mL，耐药点≥4μg/mL。
由表2可知：吉米沙星表现出对多粘菌素B最优的增敏作用，能将多粘菌素B的MIC降低4096倍(512μg/mL至0.125μg/mL)。
实施例2
吉米沙星增敏多粘菌素B抑制DK2生长具有浓度依赖性的实验。
(1)实验材料和方法：同“实施例1”。
(2)实验结果：结果见表3。
表3
a指对于DK2，与相应浓度的吉米沙星联用时多粘菌素B的MIC。
由表3可知，吉米沙星可以浓度依赖性的增敏多粘菌素B对DK2产生生长抑制作用，其中吉米沙星为1μg/mL时增敏作用最好。
实施例3
吉米沙星、恩诺沙星和司帕沙星增敏粘菌素(Colistin)对DK2产生生长抑制作用的实验。
(1)实验材料和方法：同“实施例1”。对于DK2，单独使用粘菌素时的MIC>1024μg/mL(说明DK2对粘菌素也已经严重耐药)。
(2)实验结果：结果如表4所示。
表4
a指对于DK2，单独使用氟喹诺酮类药物的MIC。
b指对于DK2，与1μg/mL的氟喹诺酮药物联用时粘菌素的MIC。
c粘菌素对铜绿的MIC敏感点≤2μg/mL，耐药点≥4μg/mL。
由表4可知，吉米沙星、恩诺沙星和司帕沙星可以增敏粘菌素对DK2产生生长抑制作用。其中吉米沙星和恩诺沙星能将粘菌素的MIC降低至临床使用范围。
实施例4
吉米沙星增敏多粘菌素B(Polymyxin B)对PAO1产生生长抑制作用的时间杀伤动力学实验。
(1)实验材料和方法
将PAO1培养过夜，用新鲜LB培养基稀释至在600nm吸光度(OD600)约为0.01。将3mL细菌悬浮液分配到四个试管中，一个试管中是吉米沙星(0.25×MIC)和多粘菌素B的组合，另外三个试管中是吉米沙星(0.25×MIC)，多粘菌素B和DMSO单独，作为对照。将试管在37℃，250rpm摇床中温育，在0,1,2,4和8小时取出等分试样，在PBS中连续稀释并接种在LB琼脂上。将板孵育24小时并测定CFU/mL。
(2)实验结果：
结果如图1所示。
吉米沙星可以增敏多粘菌素B对PAO1产生生长抑制作用。吉米沙星与多粘菌素B的增敏组合相比单独使用多粘菌素B，细菌数量减少3.7log CFU/mL(>2log CFU/mL)，认为有增敏作用(Ayerbe-Algaba,Front Cell Infect Microbiol,2018,8,e348)。
实施例5
吉米沙星可以增加DK2和PAO1细胞外膜通透性的NPN细胞膜通透性实验。
(1)实验材料和方法
收获中间对数期的每种菌株细胞(OD600～0.5)，洗涤，并重悬于ph 7.2的5mMHEPES缓冲液中。在测量荧光之前，立即将100μL体积的细胞加入100μL含有10μM NPN和1％TritonX-100或10mM EDTA或不同浓度吉米沙星的96孔板的缓冲液中。具有NPN的缀合物未处理的细胞悬浮液充当阴性对照，并且从实验数据中减去光谱读数以解释任何背景荧光。在Tecan Spark 10M读数器上在3分钟内记录该值，激发波长为360nm，发射波长为420nm。每个测定至少进行三次。结果表示为相对荧光单位。
(2)实验结果
结果如图2所示，
由图2可知，吉米沙星具有优于阳性对照EDTA显著增加DK2细胞外膜通透性的能力，具有能够增加PAO1细胞外膜通透性的能力，且这种能力具有浓度依赖性，该结果部分验证了吉米沙星增敏多粘菌素B对DK2和PAO1产生生长抑制作用的机制。
Claims (4)
1.氟喹诺酮类药物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用；
其中，所述的氟喹诺酮类药物是吉米沙星，司帕沙星，恩诺沙星，环丙沙星，沙氟沙星，莫西沙星，培氟沙星，妥舒沙星，奥比沙星，普卢利沙星，马波沙星，左氧氟沙星，氟甲喹或/和帕珠沙星；
所述铜绿假单胞菌(P.aeruginosa)是铜绿假单胞菌(P.aeruginosa)DK2或铜绿假单胞菌(P.aeruginosa)PAO1；
所述铜绿假单胞菌(P.aeruginosa)抑制剂是多粘菌素B(Polymyxin B)或粘菌素(Colistin)。
2.一种药物组合物，其包括：权利要求1所述氟喹诺酮类药物、多粘菌素B(PolymyxinB)或粘菌素(Colistin)和药学上可接受稀释剂和赋形剂；
其中，氟喹诺酮类药物与多粘菌素B(Polymyxin B)或粘菌素(Colistin)的质量比(0.001～10):1。
3.如权利要求2所述的药物组合物在制备铜绿假单胞菌(P.aeruginosa)抑制剂的增敏剂中的应用；或，
所述药物组合物在制备治疗和/或预防由铜绿假单胞菌(P.aeruginosa)引起的细菌感染疾病的药物中的应用；
其中，铜绿假单胞菌(P.aeruginosa)是DK2或PAO1；所述铜绿假单胞菌(P.aeruginosa)抑制剂是多粘菌素B(Polymyxin B)或粘菌素(Colistin)；
所述由铜绿假单胞菌(P.aeruginosa)引起的细菌感染疾病包括：由铜绿假单胞菌(P.aeruginosa)感染引起的囊性纤维化，医院获得性肺炎，呼吸机相关性肺炎和血流感染。
4.如权利要求3所述的用途，其特征在于，其中所用的氟喹诺酮类药物为吉米沙星，司帕沙星，恩诺沙星，环丙沙星，沙氟沙星，莫西沙星或/和帕珠沙星。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910692481.XA CN110448693A (zh) | 2019-07-30 | 2019-07-30 | 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910692481.XA CN110448693A (zh) | 2019-07-30 | 2019-07-30 | 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110448693A true CN110448693A (zh) | 2019-11-15 |
Family
ID=68483921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910692481.XA Pending CN110448693A (zh) | 2019-07-30 | 2019-07-30 | 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110448693A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518147A (zh) * | 2020-04-29 | 2020-08-11 | 华东理工大学 | 苯甲酰苯胺类化合物及在制备铜绿假单胞菌抑制剂的增敏剂中的应用 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103381271A (zh) * | 2007-05-22 | 2013-11-06 | 诺瓦提斯公司 | 治疗生物膜形成的三唑化合物 |
| WO2015112977A1 (en) * | 2014-01-27 | 2015-07-30 | Susanne Gardner | Antimicrobial formulations and applications thereof |
| WO2019070586A1 (en) * | 2017-10-02 | 2019-04-11 | Aridis Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR P. AERUGINOSA INFECTIONS |
-
2019
- 2019-07-30 CN CN201910692481.XA patent/CN110448693A/zh active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103381271A (zh) * | 2007-05-22 | 2013-11-06 | 诺瓦提斯公司 | 治疗生物膜形成的三唑化合物 |
| WO2015112977A1 (en) * | 2014-01-27 | 2015-07-30 | Susanne Gardner | Antimicrobial formulations and applications thereof |
| WO2019070586A1 (en) * | 2017-10-02 | 2019-04-11 | Aridis Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR P. AERUGINOSA INFECTIONS |
Non-Patent Citations (1)
| Title |
|---|
| SÜNJE JOHANNA PAMP等: "Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes", 《MOLECULAR MICROBIOLOGY》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111518147A (zh) * | 2020-04-29 | 2020-08-11 | 华东理工大学 | 苯甲酰苯胺类化合物及在制备铜绿假单胞菌抑制剂的增敏剂中的应用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Agarwal et al. | Inhaled bacteriophage-loaded polymeric microparticles ameliorate acute lung infections | |
| Weber-Dąbrowska et al. | Bacteriophage procurement for therapeutic purposes | |
| Gilbert et al. | Effect of the concentrations of magnesium and calcium on the in-vitro susceptibility of Pseudomonas aeruginosa to gentamicin | |
| US20180055895A1 (en) | Bacteriophage-containing therapeutic agents | |
| Düzgüneş et al. | Bacteriophage therapy of bacterial infections: the rediscovered frontier | |
| Krut et al. | Strain-specific association of cytotoxic activity and virulence of clinical Staphylococcus aureus isolates | |
| Gonzalez-Escobedo et al. | Identification of Salmonella enterica serovar Typhimurium genes regulated during biofilm formation on cholesterol gallstone surfaces | |
| Jha et al. | In vitro study of virulence potential of Acinetobacter baumannii outer membrane vesicles | |
| El-Banna et al. | Modulation of antibiotic efficacy against Klebsiella pneumoniae by antihistaminic drugs | |
| Moody et al. | In vitro susceptibility of Pseudomonas cepacia and Pseudomonas maltophilia to trimethoprim and trimethoprim-sulfamethoxazole | |
| Zagaliotis et al. | Therapeutic bacteriophages for Gram-negative bacterial infections in animals and humans | |
| CN110448693A (zh) | 氟喹诺酮类药物作为多粘菌素类抗生素增敏剂的应用 | |
| Cobongela et al. | Acyldepsipeptide analogues: a future generation antibiotics for tuberculosis treatment | |
| Rahal Jr et al. | Pseudomonas cepacia tricuspid endocarditis: treatment with trimethoprim, sulfonamide, and polymyxin B | |
| Mortensen et al. | In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis | |
| CN107073073A (zh) | 经肺施用绿脓菌素用于治疗细菌性呼吸道感染 | |
| JPH0820510A (ja) | 抗菌活性のある香辛料、およびこれを原料とする抗菌剤 | |
| Maderazo et al. | Activity of minocycline against Acinetobacter calcoaceticus var. anitratus (syn. Herellea vaginicola) and Serratia marcescens | |
| Nicholls et al. | Class-Driven Synergy and Antagonism between a Pseudomonas Phage and Antibiotics | |
| de Oliveira et al. | An overview of the antimicrobial activity of polymeric nanoparticles against Enterobacteriaceae | |
| TW201130497A (en) | A new lytic phage specific to Klebsiella pneumoniae in medication prodection for treating Klebsiella pneumoniae infection related liver abscesses and bacteremia | |
| Palaniappan et al. | Therapeutic efficacy of bacteriophages | |
| CN105168139B (zh) | 银包钯纳米制剂在制备抗隐球菌感染药物中的应用 | |
| Murphy et al. | Synergistic activity of repurposed peptide drug glatiramer acetate with tobramycin against cystic fibrosis Pseudomonas aeruginosa | |
| Chen et al. | In vitro and in vivo effects of the polymyxin-vorinostat combination therapy against multidrug-resistant Gram-negative pathogens |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20191115 |
|
| WD01 | Invention patent application deemed withdrawn after publication |